This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rossi, G. R. Articles by Link, C. J. Search for Related Content PubMed PubMed Citation Articles by Rossi, G. R. Articles by Link, C. J.

Effective Treatment of Preexisting Melanoma with Whole Cell Vaccines Expressing (1,3)-Galactosyl Epitopes

¹ NewLink Genetics Corp., ISU Research Park, Ames, Iowa and ² Iowa Cancer Research Foundation, Urbandale, Iowa

Requests for reprints: Gabriela R. Rossi, NewLink Genetics Corp., ISU Research Park, 2901 South Loop Drive, Suite 3900, Ames, IA 50010-8646. Phone: 515-296-3269; E-mail: grossi{at}linkp.com.

The hyperacute immune response in humans is a potent mechanism of xenograft rejection mediated by complement-fixing natural antibodies recognizing (1,3)-galactosyl epitopes (Gal) not present on human cells. We exploited this immune mechanism to create a whole cell cancer vaccine to treat melanoma tumors. B16 melanoma vaccines genetically engineered to express Gal epitopes (B16Gal) effectively treated preexisting s.c. and pulmonary Gal-negative melanoma (B16Null) tumors in the (1,3)-galactosyltransferase knockout mouse model. T cells from mice vaccinated with B16Gal recognized B16Null melanoma cells measured by detection of intracellular tumor necrosis factor-. We showed successful adoptive transfer of immunity to recipient mice bearing lung melanoma metastasis. Mice receiving lymphocytes from donors previously immunized with B16Gal had reduced pulmonary metastases. The transfer of lymphocytes from mice vaccinated with control vaccine had no effect in the pulmonary metastasis burden. This study unequivocally establishes for the first time efficacy in the treatment of preexisting melanoma tumors using whole cell vaccines expressing Gal epitopes. Vaccination with B16gal induced strong long-lasting cell-mediated antitumor immunity extended to B16Null. These data formed the basis for the testing of this therapeutic strategy in human clinical trials currently under way.

This article has been cited by other articles:

				U. Galili, K. Wigglesworth, and U. M. Abdel-Motal Intratumoral Injection of {alpha}-gal Glycolipids Induces Xenograft-Like Destruction and Conversion of Lesions into Endogenous Vaccines J. Immunol., April 1, 2007; 178(7): 4676 - 4687. [Abstract] [Full Text] [PDF]